Interesting to see how screwed up the business people get this! They give MK3475 the edge over Nivolumab because of reported side effects to Yervoy– and this is who we trust with our 401K.
Interesting to see how screwed up the business people get this! They give MK3475 the edge over Nivolumab because of reported side effects to Yervoy– and this is who we trust with our 401K.
Interesting to see how screwed up the business people get this! They give MK3475 the edge over Nivolumab because of reported side effects to Yervoy– and this is who we trust with our 401K.
Foolish, indeed, for them to think one company will "win" – our experiences on this board demonstrate that many different treatments are needed.
Hazel
Viewing 5 reply threads
You must be logged in to reply to this topic.
About the MRF Patient Forum
The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.
The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.
.
.
